Travere Announces Proposed Convertible Senior Notes Offering to Refinance 2029 Convertible Notes

robot
Abstract generation in progress

Travere Therapeutics announced its intention to offer $400 million in convertible senior notes due 2032, with an option for underwriters to purchase an additional $60 million. A portion of the proceeds will be used to repurchase outstanding 2.25% senior convertible notes due 2029, with the remainder allocated for general corporate purposes. J.P. Morgan, Jefferies, and Leerink Partners are acting as joint book-running managers.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin